Barclays PLC reissued their overweight rating on shares of Shire PLC (LON:SHP) in a report issued on Friday morning. Barclays PLC currently has a GBX 6,500 ($84.56) price objective on the biopharmaceutical company’s stock.
A number of other brokerages also recently commented on SHP. Societe Generale lowered their price objective on Shire PLC from GBX 6,500 ($84.56) to GBX 6,200 ($80.66) and set a buy rating for the company in a research report on Monday, March 6th. Royal Bank of Canada reissued an outperform rating on shares of Shire PLC in a research report on Monday, March 13th. Liberum Capital reissued a buy rating and set a GBX 5,500 ($71.55) price objective on shares of Shire PLC in a research report on Thursday, March 9th. Deutsche Bank AG reissued a buy rating on shares of Shire PLC in a research report on Tuesday, February 28th. Finally, Goldman Sachs Group Inc reissued a conviction-buy rating and set a GBX 6,800 ($88.46) price objective on shares of Shire PLC in a research report on Thursday, March 16th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of GBX 6,108.38 ($79.46).
Shares of Shire PLC (LON:SHP) opened at 4778.50 on Friday. The company’s market capitalization is GBX 43.20 billion. The stock has a 50 day moving average of GBX 4,636.64 and a 200-day moving average of GBX 4,661.74. Shire PLC has a 12-month low of GBX 2,707.19 and a 12-month high of GBX 5,377.00.
ILLEGAL ACTIVITY NOTICE: “Shire PLC (SHP) Receives “Overweight” Rating from Barclays PLC” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://sportsperspectives.com/2017/05/25/shire-plc-shp-receives-overweight-rating-from-barclays-plc.html.
In other Shire PLC news, insider William Burns purchased 136 shares of the stock in a transaction that occurred on Friday, March 31st. The stock was purchased at an average cost of GBX 4,742 ($61.69) per share, with a total value of £6,449.12 ($8,389.64).
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.